Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 3/20 | 0.46 |
| ▸ | BTK | Q06187 | 2/20 | 0.42 |
| ▸ | ROCK2 | O75116 | 12/20 | 0.38 |
| ▸ | ROCK1 | Q13464 | 7/20 | 0.38 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.36 |
| ▸ | KIF11 | P52732 | 1/20 | 0.36 |
| ▸ | INSR | P06213 | 1/20 | 0.36 |
| ▸ | MET | P08581 | 1/20 | 0.36 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.35 |
| ▸ | RET | P07949 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14320576 | 0.95 | SYK (0.47) | SYKBTKROCK2ROCK1EIF2AK2 | |
| SCHEMBL14320426 | 0.85 | SYK (0.44) | SYKINSRMETKDR | |
| SCHEMBL15651190 | 0.84 | KIF11 (0.38) | SYKBTKKIF11INSRMET | |
| SCHEMBL14320613 | 0.84 | BTK (0.42) | SYKBTKROCK2ROCK1KIF11 | |
| SCHEMBL15651869 | 0.83 | SYK (0.48) | SYKBTKROCK2ROCK1EIF2AK2 | |
| SCHEMBL15650370 | 0.82 | SYK (0.46) | SYKBTKROCK2ROCK1EIF2AK2 | |
| SCHEMBL14320504 | 0.82 | PDE5A (0.44) | SYKBTKROCK2ROCK1INSR | |
| SCHEMBL15651130 | 0.82 | CYP1A2 (0.47) | KIF11INSRMET | |
| SCHEMBL15650996 | 0.82 | JAK1 (0.41) | SYKBTKKIF11INSRMET | |
| SCHEMBL15652742 | 0.81 | JAK2 (0.49) | SYKBTKKIF11INSRMET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9637491-B2 | Pyrazolo[4,3-D]pyrimidines as kinase inhibitors | ORIGENIS GMBH (DE) | 2017-05-02 | — | — | US | claimed |
| US-20150266882-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2015-09-24 | — | — | US | claimed |
| US-9637491-B2 | Pyrazolo[4,3-D]pyrimidines as kinase inhibitors | ORIGENIS GMBH (DE) | 2017-05-02 | — | — | US | disclosed |
| US-20150266882-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2015-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150266882-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | LRRK2, MYLK2, MYLK | SYK 9/4885BTK 8/4885ROCK2 258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.